Sponsor content
34 result(s) found, displaying 1 to 10
-
Cancellation by sponsorRequested by Alexion Pharmaceuticals Australasia Pty Ltd
-
Designation or determinationOrphan drug
-
Cancellation by sponsorRequested by Alexion Pharmaceuticals Australasia Pty Ltd
-
Cancellation by sponsorRequested by Alexion Pharmaceuticals Australasia Pty Ltd
-
May-2026Prescription medicine evaluationActive ingredient: gefurulimab.
-
Prescription medicine registrationActive ingredients: selumetinib sulfate.
-
Australian Public Assessment Report (AusPAR)VOYDEYA (danicopan) is indicated as an add-on to ravulizumab or eculizumab for the treatment of the signs or symptoms of extravascular haemolysis in adult patients with paroxysmal nocturnal haemoglobinuria.
-
ARTGAustralian Register of Therapeutic Goods (ARTG) information for VOYDEYA danicopan 100 mg film-coated tablets, bottle.
-
ARTGAustralian Register of Therapeutic Goods (ARTG) information for VOYDEYA 50 + 100 mg film-coated tablets, composite bottle pack.
-
Prescription medicine registrationActive ingredients: danicopan.